In this interview, Dr. Zaiba Malik talks with Dr. Rahul Khurana about the intravitreal injection protocols for the treatment of wet age-related macular degeneration (AMD). Based on outcomes from the CATT study and other FDA phase III data, Dr. Khurana provides a short overview of the current anti-VEFG options and the relative costs associated with bevacizumab (Avastin), ranibizumab (Lucentis), and aflibercept (Eylea).

Financial Disclosures: Dr. Khurana is a paid consultant to Allergan, Genentech, iScience, and Regeneron.